Cargando…
Advances in genetics. Volume 84 /
The field of genetics is rapidly evolving, and new medical breakthroughs are occurring as a result of advances in our knowledge of genetics. This series continually publishes important reviews of the broadest interest to geneticists and their colleagues in affiliated disciplines.
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Waltham, MA :
Elsevier Science,
2013.
|
| Edición: | First edition. |
| Temas: | |
| Acceso en línea: | Texto completo Texto completo |
Tabla de Contenidos:
- Front Cover; Advances in Genetics; Copyright; Contents; Contributors; Chapter One: Diverse Roles for MAPK Signaling in Circadian Clocks; 1. Circadian Clocks; 1.1. The beginning; 1.2. Organization of the circadian clock; 2. MAPK Signaling Pathways; 2.1. General organization; 2.2. ERK MAPK; 2.3. p38 MAPK; 2.4. JNK MAPK; 3. The Function of MAPKs in Circadian Input Pathways; 3.1. ERK MAPK pathway; 3.2. ERK signaling through downstream components; 3.3. ERK MAPK in peripheral tissues; 3.4. p38 MAPK pathway; 3.5. p38 MAPK in peripheral tissues; 3.6. JNK MAPK pathway; 3.7. Summary
- 4. Endogenous Rhythms in MAPK Activation4.1. ERK in the SCN; 4.2. p38 and JNK MAPK; 4.3. Transcriptional regulation of MAPK components; 4.4. Transcriptional regulation of MAPK components in mammalian peripheral tissue; 4.5. Rhythmic MAPK activity gates input to the circadian clock; 5. MAPKs Modulate the Circadian Oscillator; 5.1. ERK-mediated regulation of the circadian oscillator; 5.2. p38-mediated regulation of the circadian oscillator; 5.3. JNK-mediated regulation of the circadian oscillator; 5.4. Future directions; 6. The Role of MAPK Pathways in Circadian Output; 6.1. ERK MAPK pathway
- 6.2. p38 MAPK pathway6.3. JNK MAPK pathway; 6.4. Future directions; 7. Concluding Remarks; References; Chapter Two: Stakeholder Views on Returning Research Results; 1. Introduction; 2. What is a Research Result?; 3. Guidelines on Returning Research Results; 3.1. Biobanks; 3.2. Population-based studies; 4. Stakeholder Views; 4.1. Researchers; 4.2. IRBs; 4.3. Research participants; 4.3.1. Vulnerable populations: Children; 4.3.2. Underserved minority populations; 4.3.3. Returning research results to relatives of research participants; 5. Extent and Experience with Returning Research Results
- 6. Overall Analysis of Stakeholder Positions6.1. Ethical; 6.2. Legal; 7. Additional Points to Consider; 7.1. Informed consent for returning research results; 7.2. Communication of research results; 7.3. Impact of returning results to affected versus healthy participants; 7.4. Provision of follow-up care; 7.5. Cost; 8. Moving Forward; Acknowledgment; References; Chapter 3: Mouse Models of Radiation-Induced Cancers; 1. Introduction; 2. RI Leukemia; 2.1. RF model; 2.2. SJL/J model; 2.3. C3H model; 2.4. CBA model; 2.5. Underlying molecular pathologies of RI leukemia; 3. RI Lymphoma
- 3.1. C57BL model3.2. BALB/c model; 3.3. NFS model; 3.4. Underlying molecular pathologies of RI lymphoma; 4. RI Lung Cancer; 4.1. C3H model; 4.2. RF model; 4.3. BALB/c model; 4.4. Underlying molecular pathologies of RI lung cancer; 5. RI Breast Cancer; 5.1. BALB/c total body irradiation model; 5.2. BALB/c transplantation model; 5.3. Underlying molecular pathologies of RI breast cancer; 6. Discussion and Conclusions; References; Chapter Four: Genomics of Elite Sporting Performance: What little We Know and Necessary Advances; 1. Introduction